Issuance of warrants
Faron issued 321,523 warrants to IPF Fund II following convertible bond amortisation.
- Warrants issued to IPF 321,523
- Total warrants held by IPF 3,641,467
- IPF interest in issued share capital approximately 1.83%
- Subscription price per warrant EUR 0.4516
Select text to share a quote on X · sign in to keep highlights & notes in your FARN notes
| Faron Pharmaceuticals Ltd | Company announcement | April 30, 2026 at 09:00:00 EEST |
TURKU, FINLAND – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company, announces that it has issued to IPF Fund II SCA, SICAV-FIAR (“IPF”) 321,523 additional warrants over ordinary shares in the Company (“Warrants”), following the the amortisation of the first and second tranche convertible bonds to Heights Capital Management, Inc.at EUR 0.4516 announced on 13 April 2026.
The subscription price of all of the Warrants held by IPF is reset to EUR 0.4516 (“Subscription Price”). As described in the Warrant Terms and Conditions announcement of 8 April 2024, in the event of any future share issue at a price lower than the Subscription Price, the Subscription Price of the Warrants will be adjusted to that lower subsequent price.
Following this issues, IPF will have an interest in 3,641,467 Warrants, representing approximately 1.83% of the issued share capital in the Company. Each Warrant entitles its holder to subscribe for one new share in the Company. The Warrants may be exercised for a period of seven years from the original date of issue.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.